Carrington's DelSite Presentation at Rodman & Renshaw Conference to be Webcast Live on November 7th
The presentation will cover DelSite's three key platform technologies inthe areas of drug delivery and vaccine adjuvants. The Company will alsoprovide an update on the development status of DelSite's lead productcandidate. To access the webcast, please log on to the following website:http://www.wsw.com/webcast/rrshq12/carn.pk.
DelSite Biotechnologies specializes in the development of novel liquid andpowder formulations for protein/peptide therapeutics and vaccines using itsproprietary platform technologies. So far this year, DelSite has signed sixtechnology rights evaluation agreements with commercial partners andinstitutions that are interested in its delivery technology.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,biopharmaceutical and consumer products company currently utilizingnaturally-occurring complex carbohydrates to manufacture and market productsfor mucositis, radiation dermatitis, wound and oral care, as well as tomanufacture and market the nutraceutical raw material Manapol(R) and cosmeticraw material Hydrapol(TM). Carrington also manufactures and markets consumerproducts and manufactures quality products for other companies. Manufacturingoperations comply with cGMP standards. Carrington's DelSite Biotechnologiessubsidiary is developing its proprietary GelSite(R) technology designed toprovide controlled release of peptide and protein-based drugs. Carrington'stechnology is protected by more than 130 patents in 26 countries. Selectproducts carry the CE mark, recognized by more than 20 countries around theworld. For more information, visit http://www.carringtonlabs.com.
About Rodman & Renshaw, LLC
Rodman & Renshaw is a full-service investment bank dedicated to providinginvestment banking services to companies that have significant recurringcapital needs due to their growth and development strategies. It alsoprovides research and sales and trading services to institutional investorclients that focus on such companies. Since 2003, Rodman has been a leadinginvestment banking firm to the biotechnology sector, a capital-intensivemarket segment, as well as a leader in the PIPE (private investment in publicequity) and RD (registered direct placements) transaction markets.
Certain statements in this release concerning Carrington may beforward-looking. Actual events will be dependent upon a number of factors andrisks including, but not limited to: subsequent changes in plans by theCompany's management; delays or problems in formulation, manufacturing,distribution, production and/or launch of new finished products; changes inthe regulatory process; changes in market trends; and a number of otherfactors and risks described from time to time in the Company's filings withthe Securities & Exchange Commission.
SOURCE Carrington Laboratories, Inc.
You May Also Like